These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15993990)

  • 1. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives.
    Arigita C; Luijkx T; Jiskoot W; Poelen M; Hennink WE; Crommelin DJ; Ley Pv; Els Cv; Kersten GF
    Vaccine; 2005 Oct; 23(43):5091-8. PubMed ID: 15993990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
    Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
    Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Kaaijk P; van Straaten I; van de Waterbeemd B; Boot EP; Levels LM; van Dijken HH; van den Dobbelsteen GP
    Vaccine; 2013 Feb; 31(7):1065-71. PubMed ID: 23273968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
    Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
    Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal meningococcal B vaccination: role of dendritic cell targeting in the development of a protective immune response.
    Arigita C; Bevaart L; Everse LA; Koning GA; Hennink WE; Crommelin DJ; van de Winkel JG; van Vugt MJ; Kersten GF; Jiskoot W
    Infect Immun; 2003 Sep; 71(9):5210-8. PubMed ID: 12933866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
    van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
    Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
    Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
    Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
    Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
    Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.
    van der Ley P; van den Dobbelsteen G
    Hum Vaccin; 2011 Aug; 7(8):886-90. PubMed ID: 21785281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.
    de Jonge MI; Hamstra HJ; Jiskoot W; Roholl P; Williams NA; Dankert J; van Alphen L; van der Ley P
    Vaccine; 2004 Sep; 22(29-30):4021-8. PubMed ID: 15364452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New vaccines require potent adjuvants like AFPL1 and AFCo1.
    Pérez O; Lastre M; Cabrera O; del Campo J; Bracho G; Cuello M; Balboa J; Acevedo R; Zayas C; Gil D; Mora N; González D; Pérez R; González E; Barberá R; Fajardo EM; Sierra G; Solís RL; Campa C
    Scand J Immunol; 2007; 66(2-3):271-7. PubMed ID: 17635804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.
    Silva Junior FC; Gioia CA; Oliveira JM; Cruz SC; Frasch CE; Milagres LG
    Scand J Immunol; 2007 Jan; 65(1):1-7. PubMed ID: 17212760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
    Marsay L; Dold C; Green CA; Rollier CS; Norheim G; Sadarangani M; Shanyinde M; Brehony C; Thompson AJ; Sanders H; Chan H; Haworth K; Derrick JP; Feavers IM; Maiden MC; Pollard AJ
    J Infect; 2015 Sep; 71(3):326-37. PubMed ID: 25982025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide.
    Zollinger WD; Babcock JG; Moran EE; Brandt BL; Matyas GR; Wassef NM; Alving CR
    Vaccine; 2012 Jan; 30(4):712-21. PubMed ID: 22138211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical contribution of both CD28 and ICOS in the adjuvant activity of Neisseria meningitidis H44/76 LPS and lpxL1 LPS.
    van Berkel ME; Schrijver EH; van Mourik A; Tesselaar K; van der Ley P; Steeghs L; Oosterwegel MA
    Vaccine; 2007 Jun; 25(24):4681-8. PubMed ID: 17499399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes.
    Arigita C; Kersten GF; Hazendonk T; Hennink WE; Crommelin DJ; Jiskoot W
    Vaccine; 2003 Feb; 21(9-10):950-60. PubMed ID: 12547608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.
    Arenas J; van Dijken H; Kuipers B; Hamstra HJ; Tommassen J; van der Ley P
    Clin Vaccine Immunol; 2010 Apr; 17(4):487-95. PubMed ID: 20107001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
    Keiser PB; Gibbs BT; Coster TS; Moran EE; Stoddard MB; Labrie JE; Schmiel DH; Pinto V; Chen P; Zollinger WD
    Vaccine; 2010 Oct; 28(43):6970-6. PubMed ID: 20732470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations.
    de Kleijn ED; de Groot R; Lafeber AB; Labadie J; van Limpt KC; Visser J; Berbers GA; van Alphen L; Rümke HC
    Vaccine; 2000 Dec; 19(9-10):1141-8. PubMed ID: 11137250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.